400898-55-7

Upstream product

• 501-53-1 benzyl chloroformate 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 27489-63-0 trans-4-<(benzyloxycarbonyl)amino>cyclohexanol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1143550-81-5 trans-[4-(2-(2-fluorophenyl)-3-phenyl-allyloxy)-cyclohexyl]-carbamic acid benzyl ester 
• 847416-39-1 N-{trans-4-[2-fluoro-2-(2-fluorophenyl)ethoxy]cyclohexyl}-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 847416-35-7 benzyl {trans-4-[2-(2-fluorophenyl)-2-hydroxyethoxy]cyclohexyl}carbamate 
• 847416-37-9 tert-butyl {trans-4-[2-fluoro-2-(2-fluorophenyl)ethoxy]cyclohexyl}carbamate 
• 847416-36-8 tert-butyl {trans-4-[2-(2-fluorophenyl)-2-hydroxyethoxy]-cyclohexyl}carbamate 
• 847416-38-0 trans-4-[2-fluoro-2-(2-fluorophenyl)ethoxy]cyclohexanamine 

Relevant academic research and scientific papers

4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.